Passage Bio is a genetic medicines company focused on developing therapies for monogenic central nervous system disorders. Co. is developing PBGM01, which utilizes a proprietary AAVhu68 capsid for the treatment of GM1 gangliosidosis. Co. is also developing PBFT02, which utilizes an AAV1 capsid for the treatment of frontotemporal dementia-progranulin deficiency. Co. is also developing PBKR03, which utilizes a proprietary AAVhu68 capsid for the treatment of Krabbe disease. Co. has various programs in the research stage under its license agreement with the Trustees of the University of Pennsylvania including: PBML04 for metachromatic leukodystrophy and PBAL05 for amyotrophic lateral sclerosis. We show 17 historical shares outstanding datapoints in our PASG shares outstanding history coverage, used to compute PASG market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing PASG market cap history over the course of time is important for investors
interested in comparing PASG's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of PASG versus a peer is one thing; comparing
PASG market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like PASG can fluctuate over the course of history.
With this page we aim to empower investors researching PASG by allowing them to research the PASG market cap history. |
Free PASG Email Alerts:
Video: The Importance of Market Cap
